- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02857699
Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies. (QoL Phase I)
A prospective cohort of 250 patients with solid tumours included in phase I clinical trials of targeted agents will be enrolled. Patients will be treated with MTA in mono therapy or in association with chemotherapy or other targeted agents in 4 large phase I centers.
Patients from trials investigating chemotherapy alone will not be included. Quality of life will be assessed during the treatment period.
연구 개요
상세 설명
The main objective of phase I dose finding studies is to identify the recommended phase II dose. The primary endpoint is the dose limiting toxicity (DLT) which is generally measured using the NCI common toxicity criteria (NCI-CTCAE) graded scale. This scale, developed for the investigation of cytotoxic chemotherapy administered in a limited number of cycles including rest period, is well adapted to identify the drug effect on organ dysfunction and life threatening events. However it may be less relevant to reflect the patient's feeling regarding the tolerability of the treatment under study resulting in over or under estimation of these toxicities.
Moreover, targeted therapies and more specifically the ones administered orally are given over long periods often with continuous schedules. Moderate toxic side effects lasting over a long period are usually not considered as DLT. The health related quality of life of patients as well as other patient reported outcome including symptom scale in addition to usual NCI CTCAE scale could be a relevant variable to detect intolerable treatments. It has not been studied prospectively to date in phase I trials.
A prospective cohort of 250 patients with solid tumours included in phase I clinical trials of targeted agents will be enrolled. Patients will be treated with MTA in mono therapy or in association with chemotherapy or other targeted agents in 4 large phase I centers.
Patients from trials investigating chemotherapy alone will not be included.
Patients included in a phase I trial will be requested to fill in
- a questionnaire of health related quality of life (the EORTC PAL 15 questionnaire)
- a questionnaire of symptoms (MDASI)
- a questionnaire on symptoms specific of MTA at baseline and at each cycle of treatment and 6 weeks after the end of treatment.
The sponsor of the therapeutic phase I trials will be informed that the present research is running and that it will not interfere with their investigational protocol. Each phase I center has the latitude to propose or not the health-related quality of life research to patients included in a given phase I trial.
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Patricia TRESCA, MD
- 전화번호: +33.1.56.24.56.30
- 이메일: chrystelle.gastrin@curie.fr
연구 장소
-
-
-
Dijon, 프랑스
- 모병
- Centre Georges Francois Leclerc
-
Paris, 프랑스, 75005
- 모병
- Institut Curie
-
Toulouse, 프랑스
- 모병
- Centre Claudius Régaud
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients with refractory solid tumor.
- Patient included in a dose finding phase I trial investigating at least one molecularly targeted agent as defined as anticancer agents that selectively target molecular pathways (including monoclonal antibodies) as opposed to DNA, tubulin or cell division machinery will be eligible.
- Phase I/II clinical trials with a dose finding component are also eligible. Trials investigating combinations of MTA with one or several cytotoxic agent(s) are eligible, as well as combinations of MTAs.
Exclusion Criteria:
- Patients with malignant hematologic disease will not be eligible.
Patients included in the following types of phase I trials are not eligible:
- Trials investigating hormonal therapy and biological therapeutics such as immunotherapy, gene therapy and vaccines alone or in combination;
- Trials of cytotoxic agents only;
- Trials investigating radiochemotherapy alone or in combination with chemotherapy or MTA
- Trials whose objectives do not include dose-finding. This includes pharmacokinetic only trials, bioequivalence trials, feasibility trials etc.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
To evaluate the association between HR QoL, patient reported symptoms and DLT.
기간: up to six months
|
To evaluate whether some toxic side events that are non dose limiting according to the phase I protocol are reported as intolerable by the patients using either specific HR QoL questionnaires or patient reported scales of symptoms
|
up to six months
|
Patient interviews : qualitative comparison versus EORTC PAL 15 questionary
기간: Up to six months
|
Identify if some dimensions of the quality of life affected by the treatment are not captured by the EORTC PAL 15 questionaries. Interviews will be realized on a sub sample of patients. An explorative qualitative research could evaluate patients' experience of the impact, burden, tolerability or acceptability of phase I anti-cancer drug trials addressing patients' perception of symptoms, functioning and overall quality of life. Interviews results contrasted with the PAL15 questionnaires will enable to determine whether a QoL questionnaire dedicated to phase I trials is necessary and what are the main components felt essential to the patients. |
Up to six months
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Xavier PAOLETTI, PhD, Gustave Roussy, Cancer Campus, Grand Paris
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
삶의 질에 대한 임상 시험
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)완전한
-
Queens College, The City University of New York모병
-
Swansea University완전한A Bite of ACT' (BOA) 수용전념치료 온라인 심리교육 과정 | 대기자 명단 제어영국
-
Hôpital Léon Bérard완전한
-
Yale-NUS College완전한연구 초점은 SGH Life Center에서 관리하는 비만 관리 설문지에 대한 환자의 반응입니다.싱가포르
-
Scripps Translational Science Institute완전한
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
Yale-NUS College완전한
-
University Hospital Inselspital, BerneDeka Medical, Inc.모집하지 않고 적극적으로
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, Inc완전한